drug · cell
LN-145
Phase 2updated 3mo agoby $IOVA IOVANCE BIOTHERAPEUTICS, INC.🔗 ChEMBL
Phase 2community read0 votes
Cell drug with a maximum clinical stage of Approval (across all indications), with an approval for cutaneous melanoma and 11 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying LN-145
- phase2A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
- phase2Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
- phase3SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- phase2A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
- phase2Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- phase1Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
- phase3Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- phase2Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
News(1)
- FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcommThe FDA's rebuff of Replimune comes a day after the agency similarly called into question the Phase 3 trial for Capricor’s Duchenne muscular dystrophy cell therapy.biospace · 14d ago
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that